Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors
Authors
Keywords
Autoimmune and inflammatory diseases, Small molecule, Kinase inhibitors, Therapeutic index, Kinase selectivity
Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 38, Issue -, Pages 127862
Publisher
Elsevier BV
Online
2021-02-19
DOI
10.1016/j.bmcl.2021.127862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
- (2021) Zhouling Xie et al. JOURNAL OF MEDICINAL CHEMISTRY
- IRAK family in inflammatory autoimmune diseases
- (2020) Lin-Chong Su et al. AUTOIMMUNITY REVIEWS
- Tuning T helper cell differentiation by ITK
- (2020) Jessica P. Elmore et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease
- (2020) Kristi A. Leonard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
- (2020) Shaodong Liu et al. MEDICINAL CHEMISTRY RESEARCH
- Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs
- (2020) Sofie Martens et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
- (2020) Peter Blomgren et al. ACS Medicinal Chemistry Letters
- Soft drugs: design principles, success stories, and future perspectives
- (2020) Peter Buchwald Expert Opinion on Drug Metabolism & Toxicology
- Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis
- (2020) Michael D. Wiese et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
- (2020) William J Sandborn et al. Journal of Crohns & Colitis
- Discovery of a Potent and Selective NF-κB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo
- (2020) Zhiqiang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of N-phenyl-7H-pyrrolo[2,3-d] pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis
- (2020) Yuqin Zhu et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTAC Technology: Opportunities and Challenges
- (2020) Hongying Gao et al. ACS Medicinal Chemistry Letters
- The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
- (2020) José M. Carballido et al. Frontiers in Immunology
- Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis
- (2020) Sebastian Torke et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
- (2020) Brian S Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
- (2020) Lauren Mifflin et al. NATURE REVIEWS DRUG DISCOVERY
- Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis
- (2020) Satheesh Nair et al. ACS Medicinal Chemistry Letters
- Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity
- (2020) James J. Crawford et al. ACS Medicinal Chemistry Letters
- JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
- (2020) Jacopo Angelini et al. Biomolecules
- ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
- (2020) Krishnarup Ghoshdastidar et al. Pharmacology Research & Perspectives
- Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
- (2020) Jian Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis
- (2020) Kristina S. Lechner et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies
- (2020) Venkateshwar Rao Gummadi et al. ACS Medicinal Chemistry Letters
- Filgotinib: First Approval
- (2020) Sohita Dhillon et al. DRUGS
- Managing toxicities of Bruton tyrosine kinase inhibitors
- (2020) Andrew Lipsky et al. Hematology-American Society of Hematology Education Program
- Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
- (2019) Liyang Shi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
- (2019) Douglas W. Thomson et al. ACS Medicinal Chemistry Letters
- NIK as a Druggable Mediator of Tissue Injury
- (2019) Lara Valiño-Rivas et al. TRENDS IN MOLECULAR MEDICINE
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)
- (2019) Scott H. Watterson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
- (2019) William T. McElroy EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk)
- (2019) Guanghui Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
- (2019) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin
- (2019) Cesar Ramirez Molina et al. BRITISH JOURNAL OF PHARMACOLOGY
- Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
- (2019) Chufeng Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors
- (2019) Hong Jia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
- (2019) Marian C. Bryan et al. JOURNAL OF MEDICINAL CHEMISTRY
- PI3K isoforms in cell signalling and vesicle trafficking
- (2019) Benoit Bilanges et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
- (2019) Xia Yao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
- (2019) Pamela A. Haile et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors
- (2019) Jun Dai et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- JAK inhibitors for the treatment of autoimmune and inflammatory diseases
- (2019) Yvan Jamilloux et al. AUTOIMMUNITY REVIEWS
- T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
- (2019) Simo Xia et al. Cellular & Molecular Immunology
- Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
- (2019) Richard D. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2019) Yaqi Kang et al. Frontiers in Pharmacology
- Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma
- (2019) Mark Zak et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity
- (2019) Naomi S. Rajapaksa et al. ACS Medicinal Chemistry Letters
- New Promise and Opportunities for Allosteric Kinase Inhibitors
- (2019) Xiaoyun Lu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Design, synthesis and structure–activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK)
- (2019) Xueying Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- ZAP-70 in Signaling, Biology, and Disease
- (2018) Byron B. Au-Yeung et al. Annual Review of Immunology
- Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
- (2018) Zhen Zhang et al. ARCHIV DER PHARMAZIE
- The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
- (2018) Jasper Rip et al. CRITICAL REVIEWS IN IMMUNOLOGY
- Fostamatinib: First Global Approval
- (2018) Anthony Markham DRUGS
- A scaffold-hopping approach to discover potent, selective and efficacious inhibitors of NF-κB inducing kinase
- (2018) Nicole Blaquiere et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
- (2018) Marian C. Bryan et al. JOURNAL OF MEDICINAL CHEMISTRY
- ABBV-105, a selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), is efficacious in multiple preclinical models of inflammation
- (2018) Christian Goess et al. Modern Rheumatology
- NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
- (2018) Hans D. Brightbill et al. Nature Communications
- Design and Synthesis of Novel 3-(2-Aminopyridin-3-yl)-1,2,4-Triazolo[4,3-b ]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors
- (2018) Chi Hoon Park et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects
- (2018) Robert Wilson et al. CLINICAL THERAPEUTICS
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
- (2018) Pamela A. Haile et al. ACS Medicinal Chemistry Letters
- Exploration of the therapeutic aspects of Lck: A kinase target in inflammatory mediated pathological conditions
- (2018) Pankaj Kumar Singh et al. BIOMEDICINE & PHARMACOTHERAPY
- Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
- (2018) Matthias Gehringer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases
- (2018) Matthew W. D. Perry et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning
- (2018) Mark E. Schnute et al. ACS Medicinal Chemistry Letters
- Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
- (2017) Katherine L. Lee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)
- (2017) Georgette M. Castanedo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
- (2017) Peter Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model
- (2017) Misato Ito et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K δ
- (2017) Rodger A. Allen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
- (2017) Kathleen M. Gillooly et al. PLoS One
- Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
- (2017) Klemens Hoegenauer et al. ACS Medicinal Chemistry Letters
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Antibody-drug conjugates for non-oncological indications
- (2016) Renhe Liu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy
- (2016) Leslie J. Crofford et al. Expert Review of Clinical Immunology
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
- (2016) Pamela A. Haile et al. JOURNAL OF MEDICINAL CHEMISTRY
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
- (2016) Alison Smith et al. Journal of Immunology Research
- Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins
- (2015) Yanou Yang et al. CHEMICAL RESEARCH IN TOXICOLOGY
- TBK1 inhibitors: a review of patent literature (2011 – 2014)
- (2015) Tao Yu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694
- (2015) Yiming Zhong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice
- (2015) Maroof Hasan et al. JOURNAL OF IMMUNOLOGY
- Human autoimmune diseases: a comprehensive update
- (2015) Lifeng Wang et al. JOURNAL OF INTERNAL MEDICINE
- Development of Selective Covalent Janus Kinase 3 Inhibitors
- (2015) Li Tan et al. JOURNAL OF MEDICINAL CHEMISTRY
- PI3K inhibitors as potential therapeutics for autoimmune disease
- (2014) Jennifer Ball et al. DRUG DISCOVERY TODAY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
- (2014) Kevin S. Currie et al. JOURNAL OF MEDICINAL CHEMISTRY
- NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis
- (2014) Ae R Noort et al. JOURNAL OF PATHOLOGY
- Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
- (2013) Klaus Okkenhaug Annual Review of Immunology
- Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures
- (2013) Kexue Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
- (2013) Mark Zak et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies
- (2012) Yan Lou et al. JOURNAL OF MEDICINAL CHEMISTRY
- NF-κB inducing kinase: A key regulator in the immune system and in cancer
- (2010) Yee Mon Thu et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now